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Abstract: Malignant pleural mesothelioma (MPM) is a rare
and aggressive cancer of the mesothelium with only a limited
range of treatment options that are largely ineffective in improv-
ing survival. Recent efforts have turned toward the analysis of
specific, dysregulated biologic pathways for insight into new
treatment targets. Epigenetic regulation of tumor suppressor
genes through chromatin condensation and decondensation has
emerged as an important mechanism that leads to tumorogenesis.
A family of histone acetyltransferases and deacetylases regulates
this balance, with the latter facilitating chromatin condensation,
thus preventing gene transcription, resulting in the loss of het-
erozygosity of tumor suppressors. Inhibition of this process,
coupled with a similar inhibition of nonhistone protein deacety-
lation, ultimately leads to the promotion of apoptosis, cell cycle
arrest, and inhibition of angiogenesis. An increasing amount of
preclinical data highlighting the effectiveness of histone deacety-
lase inhibition in MPM cell lines and mouse xenograft models
has led to a number of early phase clinical trials in patients with
MPM. The results of these efforts have led to a multicenter,
randomized, placebo-controlled phase III study of the histone
deacetylase inhibitor vorinostat in patients with advanced MPM,
offering hope for a new and effective therapy in patients with this
disease.
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Malignant pleural mesothelioma (MPM) is a rare andaggressive cancer that arises from the mesothelial
cells that line the pleural cavity. The incidence in the
United States has increased over time, with 2000 to 3000
cases now diagnosed annually. The mortality rate is high:
more than 80% of patients present with late stage disease,
and the median survival does not exceed 12 months.1 Its
association with asbestos exposure was first recognized in
1960.2 Studies using Surveillance, Epidemiology, and End
Results data show current and predicted incidences of
disease mirroring trends in asbestos use during the last
century, with a latency of 20 to 40 years between peak
consumption in the 1950s and 1960s to peak incidence of
disease during this decade.3,4
The current treatment options for patients with MPM
are limited and largely ineffective. Surgical options include
thoracoscopy for palliation, pleurectomy/decortication, and
extrapleural pneumonectomy, the last two of which can be
offered in only a minority of patients, both for reasons of
advanced disease and comorbid conditions.5–8 More recently,
the use of induction chemotherapy before extrapleural pneu-
monectomy and postoperative radiation therapy has shown
promise for improved outcomes.9,10 With regards to systemic
therapy, a great number of early phase trials of chemotherapy
and novel therapeutics have been conducted, but with disap-
pointing results.11 Phase III trials have demonstrated im-
proved survival with an antifolate plus cisplatin over treat-
ment with cisplatin alone.12,13 Although these data provided
the basis for a new standard in the first-line treatment of
patients with unresectable disease, survival was improved by
only a few months, and overall survival remains poor. The
search for new, effective therapies that capitalize on the
biology of MPM continues.
Epigenetic Regulation
Epigenetic modification has emerged as an important
mechanism leading to tumorogenesis. These changes, dis-
tinct from the processes of mutagenesis, maintain a degree
of heritability that provide the cancer cell an additional
means by which to avoid the regulatory mechanisms that
limit cell growth and proliferation. Both hypermethylation
and histone regulation have been linked to the develop-
ment of MPM. Data supporting the former, in which CpG
islands within gene promoters are methylated and silenced,
is sparse and based on the identification of simian virus 40
viral sequences in mesothelioma cell lines and tumor
samples, with increased tumor suppressor gene methyl-
ation found in simian virus 40 large T-antigen containing
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specimens.14,15 Data for the latter is more robust and helps
to provide a basis for ongoing trials in MPM using inhib-
itors of histone deacetylation.
Histones are a family of basic proteins that serve as
structural and regulatory components of chromatin. Chroma-
tin is comprised of DNA, RNA, and both histone and non-
histone elements and serves to pack linear DNA efficiently
within the cell. The fundamental subunit of chromatin is the
nucleosome, which winds 147 bp of DNA around an octamer
of histone subunits.16 Transcriptional activity can only occur
when nucleosomes are decondensed as euchromatin, in a
process that couples methylation of DNA with, among other
reactions, methylation, acetylation, and phosphorylation of
histones (Figure 1, top).16
Among these biochemical modifications, histone acet-
ylation, controlled by a family of acetyltransferases and
deacetylases (HDACs), has emerged as clinically impor-
tant.17 Much of this interest has focused on HDACs, which
serve to remove lysine residues from histone tails and non-
histone proteins, thereby preventing chromatin relaxation and
gene transcription (Figure 1, left). Four classes of HDACs
have been characterized, grouped in part by homology and in
part by cellular localization, with aberrant recruitment and
overexpression found in a wide range of cancers.18–25 A host
of pharmacologic inhibitors have also been identified, divided
by both structure and specificity for the different classes of
HDACs.26
Histone Acetylation and MPM
In vitro data for the role of HDAC inhibition in MPM
has centered on apoptosis, although the biologic effects of
HDAC inhibitors (HDACi) are diverse and include cell
cycle arrest, angiogenic inhibition, immunomodulation,
and direct acetylation of signaling intermediates and tran-
scription factors (Figure 1, bottom).26 The relevant studies
include work by Cao et al.,27 who found a decrease in the
expression of the antiapoptotic protein bcl-XL and the
induction of apoptosis in MPM cell lines treated with
sodium butyrate. Suberoylanilide hydroxamic acid was
also found to sensitize MPM cells to TNF-related apopto-
sis-inducing ligand-mediated apoptosis, with strong down-
regulation of bcl-XL.28 Depsipeptide was similarly cytotoxic to
MPM cells, an effect synergistically increased with flavopiridol,
a cyclin dependent kinase inhibitor.29
More recently, caspase-dependent apoptosis has
emerged as an important mechanism. Treatment of TNF-
related apoptosis-inducing ligand-induced MPM cell lines
with the HDACi LBH589 was found to increase caspase 3
and 7 expression in addition to apoptosis. This expression
was linked to the degradation of the antiapoptotic protein
X-linked inhibitor of apoptosis protein.30 Similarly, treat-
ment of MPM cell lines with valproic acid increased
caspase-dependent apoptosis when coupled with cisplatin
and pemetrexed.31 This work by Vandermeers et al. was
important in its study of HDACi alone and in combination
with chemotherapy. In particular, while chemotherapy re-
liably led to increased annexin V staining and an increase
in the sub-G1 population, HDACi monotherapy did so in
only one of three cell lines tested. In addition, treatment
with valproic acid plus chemotherapy led to a synergistic
increase in reactive oxygen species formation and annexin
FIGURE 1. Schematic representation of the targets and effects of HDAC inhibitors (HDACi). In addition to directly regulating
transcription through changes in chromatin structure, HDACi modulate the acetylation of transcription factors and other non-
histone proteins, leading to a range of biologic effects, including the promotion of apoptosis, cell cycle inhibition, immune
modulation, and inhibition of angiogenesis.
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V staining. Remarkably, a mouse xenograft model in this
study showed complete suppression of human epithelioid
MPM growth following treatment with valproic acid and
chemotherapy, a response not seen with either valproic
acid or chemotherapy alone.31
Indirect evidence for the importance of histone acety-
lation in MPM came from research by Shao et al.32 on the
regulation of the tumor suppressor Wilms tumor-1 (WT-1).
While its expression in lung tumors is restricted to MPM,
little mechanistic data regarding this link had been pub-
lished.33,34 In their study, Shao et al.32 found a decrease in
WT-1 reporter activity and mRNA expression in 293T cells
following overexpression of HDAC4 and HDAC5. This ac-
tivity was reversed by cotransfection of the histone acetyl-
transferase p300, which was also found to increase histone
H3 acetylation at the WT-1 intronic enhancer. Synergistic
reporter activity was seen with the cotransfection of p300 and
the transcription factors Sp1 (Specificity protein 1), c-Myb
(Myeloblastosis oncogene homolog), and Ets-1 (Erythroblas-
tosis E26 oncogene homolog 1), suggesting a role for histone
acetylation in facilitating the interaction between transcrip-
tion factors and the WT-1 gene, highlighting a possible target
for HDAC inhibition in MPM.
Clinical Studies
Data for the effectiveness of HDACi in patients with
MPM emerged in 2005, with the publication of a phase I
study of vorinostat in patients with advanced solid tu-
mors.35,36 Of the 73 patients treated, 13 held diagnoses of
MPM. Six of the patients remained in the study for greater
than 4 months. Four of these patients (30%) were found to
have stable disease. Two patients met criteria for a radio-
graphic partial response, though these were ultimately
unconfirmed.36 Nevertheless, at the time of analysis, these
patients were alive 27 and 21 months after initiating
treatment, exceeding their predicted survival. Hematologic
toxicity was mild. Fatigue and nausea/vomiting were the
most common grade III toxicities (23%). A separate phase
I study of vorinostat in combination with carboplatin and
paclitaxel in patients with advanced solid tumors also led
to disease stabilization in the single patient with MPM.37
These results were sufficiently compelling to lead to the
initiation of a multicenter, randomized, placebo-controlled
phase III study of vorinostat in patients with advanced
MPM.38
In this trial, patients who have progressed or relapsed
following treatment with pemetrexed and cisplatin or carbo-
platin are randomized 1:1 to receive vorinostat 300 mg twice
daily or a placebo (Figure 2). Medication is provided over 3
consecutive days per week in a 3-week cycle. The primary
end point is overall survival, with secondary endpoints in-
cluding objective response by RECIST, progression-free sur-
vival, pulmonary function, and quality of life. The planned
target accrual is 660 patients. The study continues after two
interim analyses.
Data from a phase II trial of a related agent, belinostat
(PXD101), in patients with advanced pleural mesothelioma has
also been published.39 Thirteen patients were enrolled, the ma-
jority of whom had received prior chemotherapy and seven of
whom had an epithelioid subtype. Three patients were able to
receive only one cycle of treatment due to symptomatic or
radiographic progression. Two patients (15%) attained stable
disease as a best response, with no partial or complete
responders. These results stand in contrast to those seen with
vorinostat and run contrary to what might have been pre-
dicted based on preclinical data, where belinostat was found
to be five-times more potent than vorinostat in in vitro growth
inhibition studies.40 This may have been due to the relative
aggressiveness of the mesothelioma in the belinostat trial, or
differences in pharmacokinetics between the two drugs as
posited by the authors.
While HDACi therapy alone seems to be effective in
advanced MPM, preclinical data, including work by Vander-
FIGURE 2. Study design for phase III trial comparing vorinostat versus placebo in patients with previously treated malignant
pleural mesothelioma (MPM).
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meers et al.,31 suggest that the coupling of HDACi therapy to
chemotherapy should be even more so.41 A number of early
phase trials in advanced solid tumors bear this out. A phase I
study of vorinostat plus cisplatin and gemcitabine in chemo-
naive advanced stage non-small cell lung cancer patients
demonstrated partial response rates of 32% (increasing to
45% if nonevaluable patients are excluded).42 Although a
comparison with standard chemotherapy alone was not pos-
sible, these rates compare favorably to historical overall
response rates of between 18 and 28% in similar patients
treated with cisplatin and gemcitabine alone.43–45 The added
benefit of vorinostat to chemotherapy was seen more
clearly in a recent randomized, placebo-controlled phase II
trial of carboplatin and paclitaxel with or without vorinos-
tat for first-line therapy for advanced non-small cell lung
cancer.46 Ninety-four patients were randomized to receive
carboplatin and paclitaxel with vorinostat 400 mg daily or
a placebo. The response rate for vorinostat was 34 versus
13% for the placebo (p  0.02). Median progression-free
survival for vorinostat and the placebo was 5.8 and 4.1
months, respectively.
Although no such study of combined therapy in MPM
has yet been conducted, a phase I trial of vorinostat in
combination with cisplatin and pemetrexed in advanced solid
tumors found an overall response rate of 10%, with 58% of
patients exhibiting stable disease, including three of five
patients (60%) with MPM.47 This combination was toxic,
with grade 3/4 dehydration in 18% of patients, fatigue in
27%, electrolyte abnormalities in 27%, and myelosuppression
in 22%. Further studies are necessary to determine the opti-
mal dosing schedule for combining vorinostat with this che-
motherapy regimen.
CONCLUSION
The need for more effective treatments for patients with
advanced MPM is clear. Several preclinical studies provide a
rationale for pursuing HDAC inhibition for the treatment of
MPM, and clinical data are emerging. Hopefully, the results
of the phase III study with vorinostat and other clinical trials
with this class of drugs will demonstrate benefit and provide
us with greater therapeutic options for our patients with
MPM.
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